December 1, 2020
Agenus launches phase 2 trial expansion in Colon Cancer for AGEN1181 in Combination with BalstilimabNew objective response in colon cancer triggers trial expansion.
August 27, 2021
Agenus is now in the closing stretch of its multidecade effort to bring a drug to market. With the FDA set to decide whether to approve PD-1 drug balstilimab in December, Agenus has published the phase 2 data it hopes will secure authorization in cervical cancer.
July 8, 2021
Agenus, an immuno-oncology company based out of Lexington, Mass., has purchased a 120-acre plot of land near Genentech's manufacturing facility in Vacaville, Cali.
May 19, 2021
BMS inked a collaboration agreement with Exscientia that can leverage AI to speed the discovery of drug candidates in therapeutic areas, including oncology and immunology.
May 18, 2021
Under the terms of the agreement, Bristol Myers Squibb will take over complete responsibility for the development and commercialization of AGEN1777 and any related products globally.
May 18, 2021
Bristol Myers Squibb, looking to the future beyond Opdivo, has penned a major biobucks pact for two early-stage assets out of small biotech Agenus.
Company Operating Status
Number of Employees (Ranges)
250 – 499
3 Forbes Road Lexington, MA 02421-7305, USA
315 Science Park Milton Road Cambridge, UK CB4 0WG
793 Heinz Ave. Berkeley, CA 94710
Place of Incorporation
Total Funding Amount (USD)
Latest Funding Round Date
August 4, 2009
Patents Assigned (Count)